WO2014066225A1 - Système d'administration d'agent actif topique à faible toxicité - Google Patents

Système d'administration d'agent actif topique à faible toxicité Download PDF

Info

Publication number
WO2014066225A1
WO2014066225A1 PCT/US2013/065868 US2013065868W WO2014066225A1 WO 2014066225 A1 WO2014066225 A1 WO 2014066225A1 US 2013065868 W US2013065868 W US 2013065868W WO 2014066225 A1 WO2014066225 A1 WO 2014066225A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
volatile
vehicle
active agent
optionally
Prior art date
Application number
PCT/US2013/065868
Other languages
English (en)
Inventor
John E. Kulesza
Original Assignee
Kulesza John E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/795,663 external-priority patent/US20130310355A1/en
Application filed by Kulesza John E filed Critical Kulesza John E
Priority to CA2888060A priority Critical patent/CA2888060C/fr
Publication of WO2014066225A1 publication Critical patent/WO2014066225A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Definitions

  • the invention relates to compositions for topical delivery of active agents.
  • the compositions relate to delivery of active agents to the skin with reduced toxicity such as drying, irritation, or inflammation.
  • the inventive composition is related to delivery of topical agents such as retinoids to the skin.
  • the comfort associated with application of topical agents is related in part to the rate of evaporation of the applied composition on the skin.
  • a product with a slo evaporation rate could feel greasy on the skin whereas a product with an overly rapid evaporation rate feels either as if it has not been applied to the skin at all or leaves the user with the impression that not enough has been applied possibly leading to overuse.
  • Combining topical agents with volatile silicones has been found to provide a pleasing application. Silicones and other organosiloxanes, however, by themselves are poor solvents for hydrophobic organic active agents.
  • Lipophilic skin care active agents such as retinoids are generally applied topically to reduce the appearance of aging, for other cosmetic purposes, or to treat a skin condition such as acne.
  • the retinoids along with many other active agents contribute to thinning or drying of the skin. This problem is worsened by including significant levels of organic solvents that themselves can alter epidermal barrier lipids and contribute to skin irritation.
  • Ethyl alcohol as used in the retinoid composition of US Patent No. 4,826,828 was believed to be the solution for topical delivery of hydrophobic agents. Ethyl alcohol, to the contrary, contributes to skin irritation and dryness.
  • combining ethyl alcohol with potentially irritating active agents increases skin dryness leading to non-optimal use,
  • An active agent delivery composition that creates pleasing administration of an active agent to the skin of a subject without a greasy feeling residue, includes only non- irritating solution components at their concentrations, and is a clear solution alone, an optionally in the presence of one or more additives.
  • the achievement of these three characteristics of an active agent delivery composition is provided by the function of a non-irritating volatile vehicle that will promote solubilization of the active agent in an organosiloxanes carrier as a primary solvent,
  • the ability of the volatile vehicle to produce a clear, fully solubilized solution is surprising in that in many embodiments the active agent is not fully soluble in either the organ osiloxane carrier or the vehicle alone at the concentrations used in the composition.
  • An inventive composition includes an active agent illustratively: vitamin A or its derivatives; hydroxy acids; benzoyl peroxide; resorcmol; antimicrobials; anti-neoplastic agents; anti-viral agents; steroidal or nonsteroidal anti-inflammatory agents; UV filters; lipids; and immunomodulators.
  • An active agent is optionally vitamin A or a derivative thereof present at between 0.001 to 2 weight percent.
  • a vitamin A derivative is a retinoid.
  • a retinoid is optionally retinal, retinoic acid, retinyl ester, retinol, tretinoin or esters thereof, isotretinoin or esters thereof, adapalene, tazarotene, or combinations thereof.
  • An active agent is optionally salicylic acid, acetylsalicylic acid, or combinations thereof,
  • the inventive composition provides pleasing skin administration through the use of an organosiloxane carrier that is optionally a linear aliphatic polyorganosiloxane, optionally ethyl trisiloxane, combined with an volatile vehicle with a complimentary' volatility relative to the carrier such that the overall composition may have an evaporation rate in air of 10 to 500 mg/cm ⁇ /minute at 25°C and atmospheric pressure of 760 mmHg, [0011 j
  • a volatile vehicle is present in the inventive composition to solubilize the active agent with the carrier while reducing or eliminating the need for an organic hydrocarbon solvent such as ethanol.
  • a vehicle is optionally a linear, branched, and/or ring formed perfluoro CJ-C20 alkyl.
  • a vehicle is a perfluoro C4-C8 alkyl, optionally a perfluoro C 6 alkyl such as perfluorohexane.
  • A. vehicle is optionally a perfluoro ether, optionally, methoxynonafluorobutane or ethoxynonafluorobutane.
  • a vehicle is optionally perfluorohexane, perfluorodecalin, methoxynonafluorobutane, pentafluoropropane, disiloxane, isododecane, isododecane in combination with an organic hydrocarbon solvent of 6 carbons or fewer and at a concentration of less than 15% per weight, a linear or branched C12-C16 alkane other than isododecane, or any combination thereof.
  • the vehicle is optionally present from about 15 to 25 percent by weight.
  • An optional organic hydrocarbon solvent of 6 carbon atoms or fewer is optionally included or is absent, optionally, the organic hydrocarbon solvent is present at less than 15 percent by weight. Optionally, the organic hydrocarbon solvent is present at less than 5 percent by weight.
  • the composition satisfies the long felt need for a system of active agent deliver ⁇ ' that does not require an alcohol solvent at concentrations in excess of 15%, which in the prior understanding was more typically of 30% or greater, to solubilize the active agent in an organosiloxane carrier.
  • the resulting compositions do not suffer the skin irritancy produced by such concentrations of organic hydrocarbon solvent, and helps reduce any irritancy that is may be a characteristic of the active agent itself.
  • the skin condition may be, for example, acne, wrinkles, dryness, cancer, or perspiration.
  • the inventive process includes applying an inventive composition to the skin of a subject
  • the invention has utility for topical delivery of active agents.
  • the invention has more specific utility for the delivery of hydrophobic active agents to the skin with reduced agent or solvent related side effects and improved comfort and user compliance.
  • Some embodiments have utility for the treatment of one or more conditions of the skin.
  • Also provided are embodiments that have utility for fully solubilizing a hydrophobic active agent in a silicone providing a clear solution with 15% or less of organic hydrocarbon having 6 carbons or fewer.
  • the inventive composition includes an active agent combined with an organosiloxane earner and a compatible volatile vehicle.
  • active agent refers to a molecule suitable for delivery to the skin or mucosal regions of a subject.
  • an active agent has pharmaceutical activity and is present for the treatment or prevention of a skin condition.
  • Active agents are optionally low polarity molecules such as those having a hydrocarbon chain of three or more carbons, but may also include materials of higher polarity.
  • active agents examples include: vitamin A or its derivatives; hydroxy acids; aromatic molecules such as benzoyl peroxide and resorcinol; azelaic acid; antimicrobials such as azelaic acid, erythromycin, sodium sulfacetamide, tetracycline and derivatives, and clindamycin; anti-neoplastic agents and/or ophthalmic agents illustratively including 5-iluorouracil, doxorubicin, imiquimod, and sodium [o-(2,6-dichloranilino) phenyl] acetate; anti-viral agents illustratively ganciclovir, trifluorothymidine and related compounds; steroidal and nonsteroidal anti-inflammatory agents illustratively flurbiprofen, ibuprofen, naproxen, indomethacin and related compounds; anti -mitotic drugs illustratively colchicine taxol and related compounds; drugs that
  • An active agent need not have pharmaceutical activity.
  • Other active agents are illustratively cosmetics such as pigments, dyes, and fillers.
  • an inventive composition optionally includes more than one active agent.
  • 2, 3, 4, 5, 6, or more active agents are present in an inventive composition.
  • An active agent is optionally a prodrug that is converted to a desired active species optionally in the skin or layer thereof.
  • An active agent is optionally a lipid such as those suitable for controlling perspiration. Lipids optionally have an HLB of less than about 12, less than about 8, or optionally less than about 6.
  • lipids include glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monoleate, diglyceryl monoisostearate, propylene of glycol monostearate, propylene glycol monoisostearate, propylene glycol monocaprylate, sorbitan monoisostearate, sorbitan monocaprylate, sorbitan monoisooieate, glyceryl monolaurate, glyceryl monocaprylate, glyceryl monocaprate, mixtures thereof or the like.
  • the lipid is glyceryl monolaurate, made available by suppliers like Fitz Chem Corporation under the name MONOMULS 90-L12.
  • the lipid when present, makes up from about 4% to about 35%, and optionally, from about 5% to about 20%, and optionally, from about 10%) to about 15%» by weight of the composition, based on total weight of the composition and including all ranges subsumed therein.
  • An active agent is optionally vitamin A or a derivative of vitamin A.
  • vitamin A or its derivatives illustratively include retinoids such as retinal, retinoic acid, retinyl ester, retinol, tretinoin or esters or amides thereof, isotretinoin or esters or amides thereof, adapalerte, tazarotene, C9 ⁇ or CI 3- cis retinoids or their derivatives (e.g. esters or amides), C13 trans retinoids or their derivatives (e.g. esters or amides), and the like.
  • Specific examples of retinoids include those described in U.S. Patent Nos. 5,837,728, 4,677,120 and 4,885,31 1 .
  • One specific example of a derivative of vitamin A is hydroxypinacolone retinoate.
  • hydroxy acids illustratively include beta hydroxy acids such as salicylic acid, acetylsalicylic acid, and the like may be substituted for or combined with the retinoid.
  • retinoids as illustrative examples of an active agent, the specification is not limited as such.
  • Other active agents are similarly operable herein. It is appreciated that other active agents are similarly substitutable with the retinoid, for example benzyol peroxide, or other active agent.
  • compositions of the invention may include 0.005 to 1.0 weight percent retinoid, in which case they are optionally applied directly to the skin, or supplied as a more concentrated solution containing higher levels of active agent, in which case prior to application they are diluted optionally by means of a cosmetically acceptable carrier to a desired level such as 0.005 to 1 .0 weight percent for retinoid, in the formulations of the in vention, water is optionally minimized or eliminated to improve the stability of retinoid and to minimize the potential for separation of the oil and water. Optionally, water is present at less than 2%.
  • a cosmetically acceptable carrier to a desired level such as 0.005 to 1 .0 weight percent for retinoid
  • water is optionally minimized or eliminated to improve the stability of retinoid and to minimize the potential for separation of the oil and water.
  • water is present at less than 2%.
  • One of ordinary skill in the art will recognize thai differing levels of active agent will be operable herein depending on the desired final amount of active agent
  • active agent is present in less than 30 percent w/w amounts.
  • active agent is present at a weight percent of 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 , 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, 0.1 , 0.01, 0.001, 0.0001 , or any level or range therebetween.
  • active agent is present at 20 percent w/w.
  • azelaic acid is an active agent it is present at 1 to 25 percent w/w
  • a vitamin A derivative is optionally present at 0.001 to 2 percent by weight.
  • Imiquimod is optionally present at 3 to 8 percent by weight.
  • Benzoyl peroxide is optionally present at 1 to 10 percent by weight. It is within the skill of the art to determine the optimal level of active agent in either a concentrated solution or a final solution for application.
  • An active agent is provided in a carrier.
  • a carrier is optionally present from 10 to 75 percent w/v.
  • a carrier is present as a predominant component in a composition.
  • a earner is present at 50% or greater w/v.
  • Carriers are optionally volatile compounds such as volatile silicones. The use of a volatile carrier allows application of the active agent to the skin and is capable of evaporating so as to leave a pleasing feel to the user.
  • the siloxanes offer excellent evaporation properties and are preferred. Siloxanes are illustratively cyclic organosiloxanes or non-cyclic organosiloxanes.
  • cyclic organosiloxanes illustratively include cyclic polydiorganosiloxanes, cyclotetradimethicones and cyclop entadimethic ones.
  • Linear organopolysiloxanes are illustratively alkyl-, alkoxy- or phenyldirnethicones, and alkyl-, alkoxy- or phenyltrimethicones.
  • a carrier is an aliphatic volatile organosiloxane. Aliphatic volatile organosiloxanes optionally have from two to six silicon atoms.
  • an aliphatic volatile organosiloxane is a linear polyorganosiloxane such as a polyorganosiloxane with 2 to 6 silicon atoms, optionally, an organo- trisiloxane, disiloxane, or combinations thereof.
  • Disiloxane itself has a very rapid evaporation profile on the skin. As such, it is optionally not used a as a carrier.
  • a carrier is ethyl trisiloxane. It is appreciated that an inventive composition optionally includes more than one carrier.
  • Suitable organosiloxane carriers preferably are a fluid that can evaporate on contact with the skin in less than one hour in a surrounding air environment at room temperature (25 °C) and standard atmospheric pressure (760 mmHg).
  • An organosiloxane earner is liquid at room temperature.
  • An organosiloxane carrier optionally has an evaporation rate ranging from 10 to 500 mg/cm 2 /minute, at 25°C and atmospheric pressure of 760 mmHg.
  • the organosiloxane carriers used in the invention have an evaporation rate ranging from 20 to 200 mg/cm 2 /minute at 25°C and atmospheric pressure of 760 mmHg.
  • the organosiloxane carriers used in the invention have an evaporation rate ranging from 100 to 200 mg/sq cm/minute at 25°C and atmospheric pressure of 760 mmHg.
  • Volatile organosiloxanes optionally are lightweight carriers that evaporate on application and thus have an elegant, light-weight "feel" on the skin. Volatile organosiloxanes, however, are typically limited in their ability to dissolve low polarity (i.e. usually greater than C7- C8)) organic compounds like retinoids. For example, when relatively low therapeutic levels of retinol (0.1-0,2% w/v) are dissolved in cyclomethicone alone, hazy solutions result due to incomplete solubilization in the organosiloxane.
  • an organic polyhalogenic vehicle alone or in combination with less than 5% low molecular weight hydrocarbon organic solvent (6 carbons or fewer), or particular volatile hydrocarbons in combination with less than 5% low molecular weight hydrocarbon organic solvent (6 carbons or fewer) could incorporate an active agent such as a retinoid at appropriate therapeutic levels and reduce the level s of low molecular weight hydrocarbon solvent to less than 5 percent in contrast to US Patent No, 4,826,828, which required 35-60 percent w/w hydrocarbon solvent.
  • organic polyhalogenic vehicles to promote solubility in organosiloxane carriers is unexpected due to the fact that organic polyhalogenic vehicles are poor solubiiizers of molecules such as retinoid on their own. Combined with the knowledge that organosiloxanes are poor solvents, one of ordinary skill in the art has no expectation of success combining two poor solubiiizers to form a system that effectively and fully solubilizes active agents.
  • Organic polyhalogenic sol vents are optionally those disclosed in US Patent No: 6,251 ,375.
  • vehicles incorporate a halogen such as one or more fluorine atoms.
  • a vehicle is optionally a substituent containing O-C20 alkyl, alkenyl, or alkynl, any of which is cyclic, bicyclic, linear, branched, or combinations thereof, wherein a substituted is a fluorine atom.
  • a vehicle is optionally a fluorine substituent containing molecule that is an aryl, a C1 -C20 alkyl, a C2-C20 alkenyl, or a C2-C20 alkynyl, wherein the molecule optionally includes a second substituent that is N, O, or S.
  • a vehicle is a perfluoro C 4 -C 12 alkyl, optionally a perfluoro C 6 alkyl such as perfluorohexane available from F2 Chemicals Ltd. (Lancashire, UK).
  • a vehicle is a bicyclic perfluoro molecule such as perfluorodecalin available from F2 Chemicals Ltd..
  • the use of perfluorodecalin produces a final composition with too low an evaporation rate resulting in a greasy feeling on the skin. As such, perfluorodecalin is optionally excluded.
  • a vehicle is a perfluoro ether.
  • a vehicle is methoxynonafiuorobutane or ethoxynonafiuorobutane available from 3M Specialty Materials, St, Paul, MN.
  • pefluro vehicles include: perfluorodimethylcyclohexane available from F2 Chemicals Ltd.; perfluoromethyldecalin available from F2 Chemicals Ltd.; perfluoropentane available from Fiuoromed, Round Rock, TX); or perfluoroperhydrophenanthrene available from F2 Chemicals Ltd.
  • a combination of one or more polyhalogenic compounds are used to form a vehicle.
  • a vehicle may be a blend of two or more of perfluorohexane, perfluorodecalin, pentafluoropropane, perfluorodimethylcyclohexane, or perfluoroperhydrophenanthrene.
  • a vehicle is a blend of perfluorohexane, perfluorodecalin, and pentafluoropropane, sol d as Fiflow BB61 sold by the Innovation Company, France.
  • a vehicle includes a particular volatile silicon containing material alone or in combination with a volatile low molecular weight hydrocarbon.
  • Illustrative volatile silicon containing materials useful as a vehicle include disiloxanes (optionally disiloxane at 0.65 - 5 cSt), among others.
  • a vehicle is not ethyl trisiloxane.
  • a vehicle is disiloxane at 5-15% by weight in combination with a volatile low molecular weight hydrocarbon present at 5% or less by weight such as ethanoi, It was discovered that the presence of disiloxane will promote the appropriate evaporation profile and can reduce the amount of organic solvent (e.g.
  • ethanoi to less than 5% by weight necessary to produce fully solubilized active agent, thus promoting the pleasing feel on the skin and creating complete solubilization (i.e. clear solution) of the active agent in the carrier.
  • a vehicle includes a volatile high molecular weight hydrocarbon such as linear or branched volatile hydrocarbons with 6 to 16 carbon atoms, alone, combined with a second or additional vehicle with a lower boiling point, or combined with less than 5% of organic solvent of 5 carbons or fewer.
  • a volatile high molecular weight hydrocarbon such as linear or branched volatile hydrocarbons with 6 to 16 carbon atoms, alone, combined with a second or additional vehicle with a lower boiling point, or combined with less than 5% of organic solvent of 5 carbons or fewer.
  • a volatile high molecular weight hydrocarbon vehicle is linear or branched and illustratively includes Cs-Ci6 aikanes, branched Cg- C i 6 esters, and mixtures thereof.
  • a volatile high molecular weight hydrocarbon vehicle is linear or branched and illustratively includes Cio-Ci6 aikanes, branched C10-C10 esters, and mixtures thereof, illustrative examples of a volatile high molecular weight hydrocarbon vehicle mclude isododecane, methylpentadecene, and isohexadecane.
  • a volatile high molecular weight hydrocarbon vehicle examples include: isododecane sold as Permethyl 99A from Presperse (Somerset, NX); a combination of isododecane, hydrogenated tetradecenyl/methylpentadecene sold as SMART-5 from IMCD, The Netherlands; isohexadecane sold as Permethyl 101 A from Presperse; the combination of CI 3-16 isoparaffin, CI 2- 14 isoparaffin, and C13-15 alkane sold as SiClone SR-5 from Presperse; the combination of coconut aikanes and coco-caprylate/eaprate sold as Vegelight 1214LC by Grant Industries (Elmwood Park, NX); coconut aikanes available from Biosynthis; and PPG-3 Benzyl ether ethylhexanoate sold as Crodamol SFX by Croda (Edison, NJ).
  • a volatile high molecular weight hydrocarbon is used in conjunction with a second vehicle with a lower boiling point.
  • a volatile high molecular weight hydrocarbon alone is typically not sufficiently volatile alone and leaves an oily feel on the skin due to this relatively low evaporation rate.
  • Supplementing the volatile high molecular weight hydrocarbon with a second vehicle of lower boiling point wi ll promote the pleasing feel in the skin by creating a desired overall compositional evaporation profile.
  • a second vehicle is optionally an organic polyhalogenic vehicle or disiloxane. Disi!oxane when used as a second vehicle is optionally of low viscosity such as 0.5 to 1.2 cSt.
  • a second vehicle is optionally present at an amount that is 30% or less by weight, optionally 25% or less by weight.
  • a volatile high molecular weight hydrocarbon is used in conjunction with an organic solvent of 5 carbons or fewer used at an overall amount of less than 5% by weight.
  • An organic solvent used as such low levels was previously thought to be unable to promote solubility in a silicone based carrier of an active agent such as a vitamin A derivative (e.g. retinoid). This explains why the art recognized knowledge preferred higher levels of organic solvents such as ethanol.
  • the high levels of ethanol i.e. more than 15%, or to a lesser degree 5% or more) promotes skin irritation. It was unexpectedly discovered that a volatile high molecular weight hydrocarbon vehicle could be combined with the low level of organic solvent of 5 carbons or fewer to have multiple beneficial effects.
  • an organic solvent of 6 carbons or fewer is ethanol, or isopropyl alcohol.
  • An organic solvent of 5 carbons or fewer when used in conjunction with a volatile high molecular weight hydrocarbon vehicle is used at 5% or fewer by weight, optionally less than 5% by weight, optionally between 2-3 percent by weight.
  • the organic solvent is preferably anhydrous.
  • a vehicle optionally has a boiling point less than 78 °C.
  • a vehicle has a boiling point below 65 °C.
  • a vehicle is optionally present at a final concentration of about 2 percent to 40 percent w./w.
  • a vehicle is present at from 1 percent to 25 percent w./w.
  • a vehicle is present at 20% w/w.
  • a vehicle is present at from 1-5% w/w, optionally less than 5% w/w. It is appreciated that more than one vehicle is optionally present in an inventive composition.
  • 2, 3, 4, 5, 6, or more vehicles are present in an inventive composition.
  • a vehicle is not a perfktoroether.
  • the inventi ve composition is optionally formulated with levels of organic sol vent.
  • An organic solvent is optionally volatile at ambient temperatures and pressures.
  • less than 35% organic solvent is included.
  • less than 30% organic solvent is included.
  • the level of volatile organic solvent is less than 15 percent w/w.
  • an organic solvent is present at 5% or less w/w, optionally an organic solvent is present at less than 5% by weight.
  • an organic solvent is absent.
  • An organic solvent is optionally an alcohol of 6 carbons or fewer.
  • an alcohol is an ethoxydiglycol, ethanol, or isopropyl alcohol.
  • an organic solvent is ethoxydiglycol present at 10 percent w/w or less.
  • Organic solvent is optionally ethanol at less than 15% by weight, optionally less than 10% by weight, optionally 5% or less by weight, optionally less than 5% by weight.
  • the level of organic solvent optionally does not induce noticeable drying or other toxic effects on the skin as opposed to systems that require volatile organic solvents such as ethanol at much higher concentrations. It is appreciated that more than one organic solvent is optionally present in an inventive composition. It is further appreciated that the inventive composition may be entirely free of organic hydrocarbon solvent of 6 or fewer carbons, optionally 5 or fewer carbons,
  • an active agent that is not fully soluble at a desired concentration in a volatile organosiloxane carrier and not ful ly soluble in a organic polyhalogenic vehicle would be fully soluble in a combination of volatile silicone carrier and organic polyhalogenic vehicle at that concentration, particularly when less than 5% of organic hydrocarbon solvent such as an alcohol (e.g. ethanol) is present, or such an organic solvent is absent.
  • a composition is optionally free of other components to promote solubility of an active agent other than the volatile organosiloxane carrier and volatile vehicle.
  • the composition is free of other components to promote solubility of an active agent other than a volatile organosiloxane carrier that is a linear organopolysiloxane (optionally ethyl trisiloxane) and a volatile vehicle that is optionally perfluorohexane, pentafluoropropane, perfluorohexane, perfluorodecalin, niethoxynonafluorobutane, disiloxane, a volatile high molecular weight hydrocarbon such as isododecane, ethanol or isopropyl alcohol at less than 15% by weight, PPG-3 Benzyl ether ethylhexanoate, or a combination thereof.
  • a volatile organosiloxane carrier that is a linear organopolysiloxane (optionally ethyl trisiloxane) and a volatile vehicle that is optionally perfluorohexane, pentafluoropropane,
  • the composition is substantially free of water, where the term substantially free of water is as low as practicably achievable in standard manufacturing conditions.
  • the absence of water helps promote a uniform clear composition that is not subject to separation of oil and water phases and is not a suspension. Also, the absence of water will stabilize hydrophobic active agents in the compositions.
  • the composition is tailored to provide a clear solution of active agent that has a desirable overall evaporation profile and does not promote unacceptable skin irritation.
  • the composition therefore includes a volatile organosiloxane carrier that when combined with the volatile vehicle creates a clear solution in the absence of water.
  • the composition has an evaporation rate of 0.01 to 15 mg cm 2 /rninute on contact with the skin or other surface at 30-32°C in an air atmosphere at room temperature (25°C) and standard atmospheric pressure (760 mmHg), and which is liquid at room temperature.
  • the composition has an evaporation rate ranging from 5-500 mg/cm 2 /minute at 25°C and atmospheric pressure of 760 mniHg.
  • the composition has an evaporation rate ranging from 10 to 200 mg ' cm 2 /minute at 25°C and atmospheric pressure of 760 mmHg.
  • evaporation of 0.3-0.6 ml the volatile components when placed on the skin will be complete in 15-60 seconds, optionally 20-40 seconds, optionally 20-30 seconds.
  • Such an evaporation profile of the composition will create the pleasing feel on the skin. Longer evaporation times produce an "oily" feel to the skin, whereas more rapid evaporation times leave the subject feeling as if nothing was applied to the skin possibly leading to overuse.
  • the composition does not promote unacceptable irritation of the skin. Skin irritation can be tested using a chromameter to measure skin redness produced by a test composition relative to that of a control or prior to application. An irritancy value in this standard art recognized test of 2.5 or less using a Minolta Chroma Meter is considered acceptable, but it is preferred that a composition have an irritancy value of less than 2, preferably less than 1.5, more preferably, 1.3 or less.
  • a composition of active agent, organosiloxane earner, and volatile vehicle is a clear liquid representing complete or visually complete solubilization of the active agent in the volatile organosiloxane carrier in the presence of the vehicle.
  • the presence of other additives may be used to alter the level of clarity, but optionally do not alter the solubilization level of the active agent.
  • a clear solution is optionally has 90% transmittance at a desired wavelength relative to the same composition absent the active agent. Transmittance is optionally 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or in excess of 99.5% at a desired wavelength relative to the same composition absent the active agent.
  • Methods of measuring transmittance using a spectrophotometer are well known in the art.
  • a non-clear solution is opaque or possesses a haze or slight haze upon visual inspection,
  • the compositions are stable in that the combination of the vehicle with the carrier will maintain the active agent in solution, and as such are capable of maintaining a clear solution at reduced temperature for a significant period of time.
  • the composition will be free of active agent crystallization at a temperature of -20 to 10°C for a period of 30 days or more.
  • the compositions are in some embodiments free of active agent crystallization at a temperature of 4°C for 30-90 days.
  • the composition optionally includes other additives or pharmaceutical carriers illustratively including: stabilizers such as the anti-oxidant BHT; surfactants illustratively Laureth- 4; anti-oxidants illustratively vitamins C and E, and Green tea extract (i.e.
  • emollients illustratively the mixture or single components of the emollient sold under the brand name SYMREPAIR available from Symrise, Teterboro, NJ.
  • additives suitable for use with the present invention such as to provide desired flow characteristics, absorption, evaporation, deliver of acti ve agent, conversion of a prodrug, or other desired characteristic.
  • a composition optionally includes one or more pigments.
  • pigments illustratively include inorganic or organic molecules such as molecules in the form of metal lakes
  • Pigments are illustratively made of titanium dioxide, zinc oxide, D&C Red No. 36 and D&C Orange No. 17, calcium lakes of D&C Red No. 7, 1 ! , 31 and 34, barium lake of D&C Red No. 12, D&C Red No. 13 strontium lake, aluminum lakes of FD&C Yellow No. 5, of FD&C Yellow No. 6, of D&C Red No. 27, of D&C Red No, 21 and of FD&C Blue No, 1 , iron oxides, manganese violet, chromium oxide and ultramarine blue.
  • compositions of the invention are also optionally diluted to the appropriate active agent level for application by using other topically acceptable compounds or vehicles that are optionally miscible with a retinoid or other active agent of the invention.
  • Other cosmetic additives are optionally employed either in the compositions of the invention or in those compositions when diluted with a suitable solvent.
  • Fully solubilized active agents produce a clear material as defined herein.
  • a process includes combining an active agent with a carrier at a concentration in which the active agent is not fully soluble in the volatile carrier.
  • a process includes combining a volatile vehicle as defined herein with an active agent and a carrier to create a clear solution.
  • An active agent is optionally vitamin A, or a vitamin A derivative such as a retinoid or derivative of a retinoid.
  • a vitamin A derivative is hydroxypinacolone retinoate or other esters or amides of 9- or 13-cis or trans-retinoids.
  • vitamin A derivatives are poorly solubilized in volatile organosiloxane carriers.
  • a volatile vehicle as defined herein surprisingly promotes visually complete solubilization of the vitamin A deri vative in the carrier in the absence of water or greater than 5% organic solvent of 5 carbons or fewer such as ethaiiol.
  • compositions illustratively including acne, wrinkles, dryness, eczema, psoriasis, actinic and nonactinic keratoses, rosaceous, among others.
  • U.S. Pat. No. 3,932,665 describes retinal as a therapeutic agent in a method for treating acne by topical application.
  • the topical administration of 5- fiuorouracil for treatment of keratoses is described in U.S. Pat. No. 4,034,1 14.
  • the inventive composition reduces the associated side effects that typically accompany topical or ophthalmologic administration of active agents while simultaneously providing a pleasing feel on the skin thereby improving patient compliance.
  • the inventive composition is suitable for topical delivery of an active agent
  • the inventive composition illustratively includes an active agent formulated in a carrier containing volatile organosiloxane and volatile vehicle.
  • active agent e.g. retinoids
  • active agent is stable when formulated in the organosiloxane carrier compositions of the invention in contrast to other conventional carriers.
  • compositions formulated as described herein with a retinoid as an active agent are optionally topically applied to the skin at a concentration that results in application of 0.005 to 1.0 weight percent retinoid, optionally 0.01 to 0.50 weight percent retinoid.
  • a composition is optionally applied in the areas where fine lines, wrinkles, dry or inelastic skin or large pores are observed.
  • a moisturizer is applied with or after application of the inventive compositions to enhance the tactile comfort associated with application of the compositions and to enhance the wrinkle effacement and other benefits achieved by the compositions.
  • An improved characteristic of the inventive composition is that the use of additional moisturizers is not required, but also not precluded.
  • compositions of the present invention are formulated to include moisturizing components that are compatible with the volatile organosiloxane carrier to a level of up to 35% by weight of the final formulation.
  • moisturizing ingredients are illustratively petrolatum, ethylhexyl palmitate, cholesterol fatty acid ceramide, and squalane.
  • the addition of one or more moisturizing components is beneficial when the inventive composition is applied to previously dried skin or under conditions where dryness commonly occurs such as in cold climates, or winter months.
  • a moisturizing component is applied where the active agent itself has a drying effect such as when retinoid or 5-fluorouracil is applied.
  • An inventive composition is optionally applied to the skin of a subject.
  • a subject is optionally a patient,
  • a subject is optionally a mammal such as humans, non-human primates, horses, goats, cows, sheep, pigs, dogs, cats, and rodents.
  • An inventive composition is optionally provided as a lotion, cream, gel, bar, ointment, or in pad form.
  • the composition is provided in a single use container the contents of which are applied directly to the stratum corneum of a subject or applied to an applicator pad for subsequent delivery to the subject,
  • Cooling effect is optionally observed upon application of the in ventive composition. Cooling effect as used herein means reducing the temperature of skin, optionally, from about 1°C to about 2°C upon application. The cooling effect includes the effect that results from carrier or vehicle evaporation.
  • inventive composition is optionally administered one to three times daily.
  • inventive composition is delivered once daily.
  • inventive composition is administered weekly, biweekly, monthly, or any subdivision thereof, It is appreciated that the inventive composition be administered for an amount of time suitable for efficacy of the active agent.
  • inventive composition is administered for one to six weeks.
  • inventive composition is administered indefinitely.
  • An inventive process illustratively includes making a first solution by solubilizing one or more active agents optionally in an organic solvent preferably performed with gentle mixing in low to no light conditions,
  • a second solution is made by mixing additives such as emollients and vitamins.
  • the second solution is added to and mixed with the first solution. Mixing is preferably in the dark under gentle mixing conditions.
  • a third solution of earlier and vehicle is made and the third solution is added to the combined first and second solutions to form a composition.
  • Mixing is optionally non-vortex, gentle mixing in low light or darkness. Mixing is preferably for 120 minutes.
  • the composition is preferably stored under inert gas such as nitrogen gas.
  • inventive process is optionally performed at ambient temperature and pressure conditions.
  • inventive process is performed by heating one or more components or solutions, (0061 j )
  • Various aspects of the present invention are illustrated by the fol lowing non -limiting examples, The examples are for illustrative purposes and are not a limitation on any practice of the present invention. It will be understood that variations and modifications can be made without departing from the spirit and scope of the invention.
  • One of ordinary skill in the art readily knows how to synthesize or commercially obtain the reagents and components described herein.
  • a Formula A composition is mixed containing 3.0 percent ethoxydiglycol, 0.5 percent Laureth-4, 0.10 percent hydroxypinacolone retinoate, 0.05 % BHT, 2.0 percent SYMREPAI , 2.0 percent tetrahexyldecyl ascorbate, 0.50 percent tocopherol, 20 percent methoxynonailuorobutane, 1.0 percent SILOX GT, and the remainder Ethyl trisiloxane.
  • Phase 1 containing Ethoxydiglycol (Transcutol CG purchased from Gattefosse. Toronto, ON, Canada), Laureth-4 (Croda, Edison, NJ), Hydrocypirtacolone retinoate (MDI-101, Concert LLC) and BHT by gentle mixing in a propeller mixer using low light conditions.
  • Phase 2 is prepared separately, Phase 2 includes SYMREPAIR (Symrise, Inc., Teterboro, NJ) which includes hexyldecanol, bisabolol, cetyl hydroxyproline palmitate, stearic acid, and Brassica campestris sterols.
  • SYMREPAIR Symrise, Inc., Teterboro, NJ
  • SYMREPAIR is mixed with tetrahexyldecyl ascorbate (BV-OSC, Barnei, Englewood Cliffs, NJ) and tocopherol USP (DSM Nutritional Products, Inc.) in a propeller mixer until a clear solution forms.
  • Phase 1 is combined with phase 2 by slow addition with continuous, non-vortex propeller mixing protecting the solutions from light.
  • Phase 3 is prepared by gentle propeller mixing at ambient temperature.
  • Phase 3 includes ethyl trisiloxane (Silsoit ETS, Monentiv, Albany, NY), methoxynonafluorobutane (3M Specialty Materials) and SILOX GT (combination of cyclopentasiloxane and Camellia sinesis leaf extract from BASF Beauty Care).
  • the combined phases 1 and 2 are slowly added to phase 3 with continuous, non-vortex propeller mixing protected from the light. Mixing is continued for 120 minutes.
  • Formula A is transferred to opaque holding containers with nitrogen head-space for storage. 60 ml., of Formula A is then transferred to 2 oz. amber glass bottles with a purified nitrogen gas head-space and stored protected from light until used.
  • Example 2
  • a Formula B solution is prepared and stored as in Example 1 with the exception that Formula B includes perfluorohexane alone or in combination with perfluorodecalin and pentafiuoropropane at 5% by weight in the place of methoxynonafluorobutane.
  • Formula B also includes 8-12% disiloxane.
  • An illustrative Formula B solution is illustrated in Table 2.
  • a Formula C solution is prepared by combining three phases and stored as in Example 1 , Formula C is as illustrated in Table 3.
  • Formula D solution is prepared by combining three phases and stored as in Exar 1 , Formula D is as illustrated in Table 4,
  • Formula E solution is prepared by combining three phases and stored as in Example 1.
  • Formula E is as illustrated in Table 5.
  • a Formula F solution is prepared by combining three phases and stored as in Example 1 , Formula F is as illustrated in Table 6,
  • a comparator solution of Formula G is prepared by combining three phases and stored in Example 1.
  • Formula G is as illustrated in Table 7.
  • compositions of Formulas A-G are also analyzed for propensity to cause skin irritancy. Eight volunteer subjects in normal health and that do not exhibit any evidence of acute or chronic disease including dermaiological or ophthalmologic problems are administered one of Formula A-H. The compositions are applied to both sides of the face in areas that are devoid of warts, nevi, moles, sunburn, suntan, scars and active dermal lesions. After an incubation time of 2 hours, measurements are made using a Minolta Chroma Meter as per the manufacturer's instructions, The values in the test area of each side of the face are averaged. Results are presented in Table 8.
  • Formula H is tested for clarity as per Example 8.
  • the blinded tester characterized the formulation as clear.
  • Formula H also demonstrates low irritancy levels when measured in the skin irritancy test of Example 8 with an irritancy level of 1.1. This is due to the low irritancy of the disiloxane and the ethyl trisiioxane, as well as the very low level of etbanol which is less than in Formula C.
  • a second comparator solution of Formula I is made containing 46.3%
  • Formula B is prepared essentially as described in U.S. Patent No. 4,826,828.
  • a split face test is performed by using test Formulas A-F and H or the comparator of Formulas G or i as follows. Twelve females aged 20 to 59 apply a single test formula to one side of their faces and a comparator to the other side once daily for eight weeks. Thin shavings of the skin on each side of the face are taken before the test begins and after the eight week test period. The skin shavings after the test are in better condition than those before the test in all twelve women in the test formula groups, The majority of the women in the comparator groups show skin improvement, but several do not. The skin of all women is both thicker and more organized after the test than before. All women in the test fommla groups report improved moisture in the tested skin whereas the comparator group issues complaints of drying and cracking of the tested skin areas.
  • a test of the ability of the Formulas A-F and H relative to the comparators of Formulas G and I to reduce skin dryness is performed with or without supplemental moisturizer. Twelve panelists who demonstrate skin dryness upon repeated soap washing of the hands are selected to participate in this study. Initially, the panelists induce a condition of dryness by washing their hands with bar soap. The test formulations are applied daily to one hand while the other is left untreated to serve as a control side. Each hand is rated randomly by two trained evaluators who have no knowledge of which hand is treated. The evaluators use a stereomicroscope to assist them with their ratings. The results of this study are expected to demonstrate that the unmoisturized comparator hand shows additional dryness compared to the control hand.
  • a Fonnula J solution is prepared wherein the active ingredient is benzoyl peroxide at 2.5 percent weight percent final.
  • a phase 1 solution is prepared at ambient temperature by combining dimethyl isosorbide at 15% w/w final, ethanol (SD-Alcohol 40-B, 200 proof) at 4.7 % w/w final, Laureth-4 at 1% w/w final, and benzoyl peroxide at 2.5% w/w final.
  • the phase 1 ingredients are combined with continuous non-vortex propeller mixing.
  • Phase 2 is formed by combination of methyl perfluorobutyl ether (and) methyl perfluoroisobutyl ether (CF-61 ) at 35% w/w final and the remainder ethyl trisiloxane with continuous non-vortex propeller mixing until a clear solution is formed.
  • Phase 2 is slowly combined with phase 1 with continuous non-vortex propeller mixing. If a hazy solution is observed it will clarify upon standing for 24-48 hours at ambient temperature.
  • Formula J is stored in 60 ml volumes with absorbent applicator pads.
  • Formula K is prepared as in Formula J with the exception that Fonnula K includes 5% by weight perfluorohexane and 8% by weight disiloxane in the place of methoxynonafluorobutane.
  • Fonnula K includes 5% by weight perfluorohexane and 8% by weight disiloxane in the place of methoxynonafluorobutane.
  • Patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are incorporated herein by reference to the same extent as if each individual application or publication was specifically and individually incorporated herein by reference.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition d'administration d'agent actif, qui permet l'administration topique d'agents actifs comprenant de la vitamine A et ses dérivés. Un véhicule volatil sert de coupleur pour un agent actif et de porteur d'organosiloxane, de façon à permettre une solubilisation complète d'agents actifs normalement non miscibles dans des silicones, et fournissant une composition à évaporation ciblée non irritante.
PCT/US2013/065868 2012-10-24 2013-10-21 Système d'administration d'agent actif topique à faible toxicité WO2014066225A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2888060A CA2888060C (fr) 2012-10-24 2013-10-21 Systeme d'administration d'agent actif topique a faible toxicite

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261717830P 2012-10-24 2012-10-24
US61/717,830 2012-10-24
US13/795,663 2013-03-12
US13/795,663 US20130310355A1 (en) 2009-12-15 2013-03-12 Low toxicity topical active agent delivery system

Publications (1)

Publication Number Publication Date
WO2014066225A1 true WO2014066225A1 (fr) 2014-05-01

Family

ID=50545145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/065868 WO2014066225A1 (fr) 2012-10-24 2013-10-21 Système d'administration d'agent actif topique à faible toxicité

Country Status (2)

Country Link
CA (1) CA2888060C (fr)
WO (1) WO2014066225A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148795A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Compositions pour le traitement de l'acné
CN110430872A (zh) * 2017-02-15 2019-11-08 博塔尼克斯制药有限公司 治疗痤疮的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160547A1 (en) * 2006-01-11 2007-07-12 Janet Duffy Method of applying a composition
US20110142769A1 (en) * 2009-12-15 2011-06-16 Kulesza John E Low toxicity topical active agent delivery system
WO2012051614A2 (fr) * 2010-10-15 2012-04-19 Kulesza John E Administration d'agents bioactifs hydrophobes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160547A1 (en) * 2006-01-11 2007-07-12 Janet Duffy Method of applying a composition
US20110142769A1 (en) * 2009-12-15 2011-06-16 Kulesza John E Low toxicity topical active agent delivery system
WO2012051614A2 (fr) * 2010-10-15 2012-04-19 Kulesza John E Administration d'agents bioactifs hydrophobes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148795A1 (fr) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Compositions pour le traitement de l'acné
CN110430872A (zh) * 2017-02-15 2019-11-08 博塔尼克斯制药有限公司 治疗痤疮的组合物
JP2020508993A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡を処置するための組成物
EP3582763A4 (fr) * 2017-02-15 2020-11-25 Botanix Pharmaceuticals Ltd Compositions pour le traitement de l'acné

Also Published As

Publication number Publication date
CA2888060C (fr) 2019-02-26
CA2888060A1 (fr) 2014-05-01

Similar Documents

Publication Publication Date Title
US10500279B2 (en) Low toxicity topical active agent delivery system
AU2002334601B2 (en) Anti-irritating rosacea treatment
US10314777B2 (en) Delivery of hydrophobic bioactive agents
ES2327901T3 (es) Metodo para preparar dispersiones que contienen ingredientes fisiologicamente activos a alta presion/alta cizalla.
AU2002334601A1 (en) Anti-irritating rosacea treatment
CA2526642A1 (fr) Compositions sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase huileuse non volatile
FR2909000A1 (fr) Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations.
US20150320867A1 (en) Topical formulations and methods for the use thereof
CA2649124A1 (fr) Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations
US20130310355A1 (en) Low toxicity topical active agent delivery system
CA2888060C (fr) Systeme d'administration d'agent actif topique a faible toxicite
ES2314365T3 (es) Utilizacion de una composicion que comprende oxido de vitamina k1 o un derivado del mismo para el tratamiento y/o la prevencion de lesiones dermatologicas en los mamiferos.
CA2911688C (fr) Compositions photoprotectrices non irritantes, non blanchissantes
US20170189294A1 (en) Non-Irritating, Non-Whitening Photoprotective Compositions
WO1994007478A1 (fr) Compositions pharmaceutiques topiques
JP2005314434A (ja) 生物におけるヒスタミン放出に関連する徴候を減じるための一のキレート剤を含む組成物の使用
KR102662132B1 (ko) 무수 실키 화장품
EP3013313A1 (fr) Compositions photoprotectrices non irritantes, non blanchissantes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13848771

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2888060

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13848771

Country of ref document: EP

Kind code of ref document: A1